The use of flutamide in hormone-refractory metastatic prostate cancer

D. G. McLeod, R. C. Benson, Mario Eisenberger, E. D. Crawford, B. A. Blumenstein, D. Spicer, J. T. Spaulding

Research output: Contribution to journalArticle

Abstract

In a recent intergroup study under the auspices of the National Cancer Institute, 603 eligible patients with newly diagnosed disseminated adenocarcinoma of the prostate were prospectively randomized in a double- blinded clinical trial to receive either a gonadotropin-releasing hormone analogue (leuprolide) and a nonsteroidal antiandrogen (flutamide) or leuprolide and placebo. Of the 603 eligible patients, 300 were in the leuprolide and placebo arm and 303 were in the leuprolide and flutamide arm. At the time of disease progression, the code was broken: Those patients in the placebo arm were given the opportunity to receive flutamide, and the patients in the flutamide arm were treated at their physician's discretion. There was no survival time distribution difference, based on survival measured from the progression data, between the patients who were received flutamide after progression and those who were treated at their physician's discretion after progression. Furthermore, the addition of flutamide to leuprolide at the time of disease progression resulted in a survival-time distribution that is similar to other treatments of hormone-refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)3870-3873
Number of pages4
JournalCancer
Volume72
Issue number12 SUPPL.
StatePublished - 1993

Fingerprint

Flutamide
Leuprolide
Prostatic Neoplasms
Hormones
Placebos
Survival
Disease Progression
Nonsteroidal Anti-Androgens
Physicians
National Cancer Institute (U.S.)
Gonadotropin-Releasing Hormone
Prostate
Adenocarcinoma
Clinical Trials

Keywords

  • cancer
  • hormone
  • metastases
  • prostate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

McLeod, D. G., Benson, R. C., Eisenberger, M., Crawford, E. D., Blumenstein, B. A., Spicer, D., & Spaulding, J. T. (1993). The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer, 72(12 SUPPL.), 3870-3873.

The use of flutamide in hormone-refractory metastatic prostate cancer. / McLeod, D. G.; Benson, R. C.; Eisenberger, Mario; Crawford, E. D.; Blumenstein, B. A.; Spicer, D.; Spaulding, J. T.

In: Cancer, Vol. 72, No. 12 SUPPL., 1993, p. 3870-3873.

Research output: Contribution to journalArticle

McLeod, DG, Benson, RC, Eisenberger, M, Crawford, ED, Blumenstein, BA, Spicer, D & Spaulding, JT 1993, 'The use of flutamide in hormone-refractory metastatic prostate cancer', Cancer, vol. 72, no. 12 SUPPL., pp. 3870-3873.
McLeod DG, Benson RC, Eisenberger M, Crawford ED, Blumenstein BA, Spicer D et al. The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer. 1993;72(12 SUPPL.):3870-3873.
McLeod, D. G. ; Benson, R. C. ; Eisenberger, Mario ; Crawford, E. D. ; Blumenstein, B. A. ; Spicer, D. ; Spaulding, J. T. / The use of flutamide in hormone-refractory metastatic prostate cancer. In: Cancer. 1993 ; Vol. 72, No. 12 SUPPL. pp. 3870-3873.
@article{5c23101b810d4fd09d3e109824119268,
title = "The use of flutamide in hormone-refractory metastatic prostate cancer",
abstract = "In a recent intergroup study under the auspices of the National Cancer Institute, 603 eligible patients with newly diagnosed disseminated adenocarcinoma of the prostate were prospectively randomized in a double- blinded clinical trial to receive either a gonadotropin-releasing hormone analogue (leuprolide) and a nonsteroidal antiandrogen (flutamide) or leuprolide and placebo. Of the 603 eligible patients, 300 were in the leuprolide and placebo arm and 303 were in the leuprolide and flutamide arm. At the time of disease progression, the code was broken: Those patients in the placebo arm were given the opportunity to receive flutamide, and the patients in the flutamide arm were treated at their physician's discretion. There was no survival time distribution difference, based on survival measured from the progression data, between the patients who were received flutamide after progression and those who were treated at their physician's discretion after progression. Furthermore, the addition of flutamide to leuprolide at the time of disease progression resulted in a survival-time distribution that is similar to other treatments of hormone-refractory prostate cancer.",
keywords = "cancer, hormone, metastases, prostate",
author = "McLeod, {D. G.} and Benson, {R. C.} and Mario Eisenberger and Crawford, {E. D.} and Blumenstein, {B. A.} and D. Spicer and Spaulding, {J. T.}",
year = "1993",
language = "English (US)",
volume = "72",
pages = "3870--3873",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12 SUPPL.",

}

TY - JOUR

T1 - The use of flutamide in hormone-refractory metastatic prostate cancer

AU - McLeod, D. G.

AU - Benson, R. C.

AU - Eisenberger, Mario

AU - Crawford, E. D.

AU - Blumenstein, B. A.

AU - Spicer, D.

AU - Spaulding, J. T.

PY - 1993

Y1 - 1993

N2 - In a recent intergroup study under the auspices of the National Cancer Institute, 603 eligible patients with newly diagnosed disseminated adenocarcinoma of the prostate were prospectively randomized in a double- blinded clinical trial to receive either a gonadotropin-releasing hormone analogue (leuprolide) and a nonsteroidal antiandrogen (flutamide) or leuprolide and placebo. Of the 603 eligible patients, 300 were in the leuprolide and placebo arm and 303 were in the leuprolide and flutamide arm. At the time of disease progression, the code was broken: Those patients in the placebo arm were given the opportunity to receive flutamide, and the patients in the flutamide arm were treated at their physician's discretion. There was no survival time distribution difference, based on survival measured from the progression data, between the patients who were received flutamide after progression and those who were treated at their physician's discretion after progression. Furthermore, the addition of flutamide to leuprolide at the time of disease progression resulted in a survival-time distribution that is similar to other treatments of hormone-refractory prostate cancer.

AB - In a recent intergroup study under the auspices of the National Cancer Institute, 603 eligible patients with newly diagnosed disseminated adenocarcinoma of the prostate were prospectively randomized in a double- blinded clinical trial to receive either a gonadotropin-releasing hormone analogue (leuprolide) and a nonsteroidal antiandrogen (flutamide) or leuprolide and placebo. Of the 603 eligible patients, 300 were in the leuprolide and placebo arm and 303 were in the leuprolide and flutamide arm. At the time of disease progression, the code was broken: Those patients in the placebo arm were given the opportunity to receive flutamide, and the patients in the flutamide arm were treated at their physician's discretion. There was no survival time distribution difference, based on survival measured from the progression data, between the patients who were received flutamide after progression and those who were treated at their physician's discretion after progression. Furthermore, the addition of flutamide to leuprolide at the time of disease progression resulted in a survival-time distribution that is similar to other treatments of hormone-refractory prostate cancer.

KW - cancer

KW - hormone

KW - metastases

KW - prostate

UR - http://www.scopus.com/inward/record.url?scp=0027445399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027445399&partnerID=8YFLogxK

M3 - Article

C2 - 8252506

AN - SCOPUS:0027445399

VL - 72

SP - 3870

EP - 3873

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12 SUPPL.

ER -